Cite
Shah PD, Wethington SL, Pagan C, et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163(2):246-253doi: 10.1016/j.ygyno.2021.08.024.
Shah, P. D., Wethington, S. L., Pagan, C., Latif, N., Tanyi, J., Martin, L. P., Morgan, M., Burger, R. A., Haggerty, A., Zarrin, H., Rodriguez, D., Domchek, S., Drapkin, R., Shih, I. M., Smith, S. A., Dean, E., Gaillard, S., Armstrong, D., Torigian, D. A., Hwang, W. T., Giuntoli, R., & Simpkins, F. (2021). Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic oncology, 163(2), 246-253. https://doi.org/10.1016/j.ygyno.2021.08.024
Shah, Payal D, et al. "Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer." Gynecologic oncology vol. 163,2 (2021): 246-253. doi: https://doi.org/10.1016/j.ygyno.2021.08.024
Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 05. PMID: 34620496.
Copy
Download .nbib